These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 32621419)

  • 1. [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].
    Yu Q; Xiong X; Sun Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(1):1-19. PubMed ID: 32621419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cullin-RING Ligases as attractive anti-cancer targets.
    Zhao Y; Sun Y
    Curr Pharm Des; 2013; 19(18):3215-25. PubMed ID: 23151137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skp1: Implications in cancer and SCF-oriented anti-cancer drug discovery.
    Hussain M; Lu Y; Liu YQ; Su K; Zhang J; Liu J; Zhou GB
    Pharmacol Res; 2016 Sep; 111():34-42. PubMed ID: 27238229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction.
    Sun Y
    Adv Exp Med Biol; 2020; 1217():1-8. PubMed ID: 31898218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Protein Neddylation to Inactivate Cullin-RING Ligases by Gossypol: A Lucky Hit or a New Start?
    Yu Q; Sun Y
    Drug Des Devel Ther; 2021; 15():1-8. PubMed ID: 33442232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of small molecule inhibitors of neddylation catalyzing enzymes for anticancer therapy.
    Qin X; Han X; Sun Y
    Biomed Pharmacother; 2024 Oct; 179():117356. PubMed ID: 39214012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of Cullin-RING E3 ubiquitin ligase-dependent ubiquitination by small molecule compounds.
    Wu K; DeVita RJ; Pan ZQ
    J Biol Chem; 2024 Mar; 300(3):105752. PubMed ID: 38354780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs.
    Gong L; Cui D; Xiong X; Zhao Y
    Adv Exp Med Biol; 2020; 1217():317-347. PubMed ID: 31898236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.
    Zhao Y; Morgan MA; Sun Y
    Antioxid Redox Signal; 2014 Dec; 21(17):2383-400. PubMed ID: 24410571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A patent review of SCF E3 ligases inhibitors for cancer：Structural design, pharmacological activities and structure-activity relationship.
    Zeng J; Chen Z; He Y; Jiang Z; Zhang Y; Dong Q; Chen L; Deng S; He Z; Li L; Li J; Shi J
    Eur J Med Chem; 2024 Nov; 278():116821. PubMed ID: 39232359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SCF E3 ubiquitin ligases as anticancer targets.
    Jia L; Sun Y
    Curr Cancer Drug Targets; 2011 Mar; 11(3):347-56. PubMed ID: 21247385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotavirus NSP1 Requires Casein Kinase II-Mediated Phosphorylation for Hijacking of Cullin-RING Ligases.
    Davis KA; Morelli M; Patton JT
    mBio; 2017 Aug; 8(4):. PubMed ID: 28851847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway.
    Zhou H; Lu J; Yang CY; Sun Y; Wang S
    Adv Exp Med Biol; 2020; 1217():349-362. PubMed ID: 31898237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
    Kitagawa K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.
    Luo Z; Pan Y; Jeong LS; Liu J; Jia L
    Autophagy; 2012 Nov; 8(11):1677-9. PubMed ID: 22874562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
    Masumoto K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cullin-RING Ligases as Promising Targets for Gastric Carcinoma Treatment.
    Song Q; Feng S; Peng W; Li A; Ma T; Yu B; Liu HM
    Pharmacol Res; 2021 Aug; 170():105493. PubMed ID: 33600940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation.
    Bulatov E; Ciulli A
    Biochem J; 2015 May; 467(3):365-86. PubMed ID: 25886174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coupled monoubiquitylation of the co-E3 ligase DCNL1 by Ariadne-RBR E3 ubiquitin ligases promotes cullin-RING ligase complex remodeling.
    Kelsall IR; Kristariyanto YA; Knebel A; Wood NT; Kulathu Y; Alpi AF
    J Biol Chem; 2019 Feb; 294(8):2651-2664. PubMed ID: 30587576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Cullin-RING E3 Ligases for Radiosensitization: From NEDDylation Inhibition to PROTACs.
    Zheng S; Tao W
    Front Oncol; 2020; 10():1517. PubMed ID: 32983997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.